ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Significant Expense Categories (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Research and development expense
Total research and development expense	$ (36,877)	$ (63,851)
General and administrative expense
Total general and administrative expense	(6,024)	(9,974)
Other expense	(50)	(59)
Net loss	(43,311)	(78,710)
Reportable Segment
Research and development expense
Clinical trials	(13,265)	(19,778)
Personnel	(9,326)	(13,238)
Contract manufacturing	(8,550)	(25,202)
Equipment, depreciation, and facility	(2,583)	(1,920)
Other research and development	(3,153)	(3,713)
General and administrative expense
Personnel	(3,777)	(5,004)
Other general and administrative	(2,247)	(4,970)
Other expense	(410)	(4,885)
Net loss	$ (43,311)	$ (78,710)